XTL Biopharmaceuticals Ltd. — FY2020 Form 20-F
Reporting period: Fiscal year ended December 31, 2020; filed March 15, 2021. This is an annual report, not a standalone fourth-quarter filing. Financial statements are audited and prepared under IFRS in U.S. dollars.
Business context
XTL is an Israel-based development-stage biopharmaceutical company focused on autoimmune diseases. Its lead candidate, hCDR1 (edratide), is described as Phase II-ready for systemic lupus erythematosus (SLE) and Sjögren’s syndrome (SS). The company has no product sales and has not commercialized a product. It also holds a small investment in InterCure Ltd. and, through its subsidiary, rights relating to rHuEPO for multiple myeloma; management does not expect material rHuEPO development activity.
Financial results and position
| Metric (US$ thousands, except per-share data) | 2020 | 2019 | Change / context |
|---|---|---|---|
| Revenue | No product sales | No product sales | No commercial revenue reported |
| Research and development expense | 38 | 35 | Up 3 |
| General and administrative expense | 910 | 807 | Up 103; attributed mainly to CEO replacement and higher directors’ and officers’ insurance |
| Operating loss | (948) | (842) | Loss widened by 106 |
| Net finance income (expense) | 166 | (505) | Improved primarily from InterCure securities revaluation |
| Net loss | (782) | (1,347) | Loss narrowed by 565 despite higher operating expenses |
| Basic and diluted loss per share | (US$0.002) | (US$0.003) | — |
| Operating cash used | 850 | 908 | Cash burn decreased by 58 |
2020 finance income included a US$138,000 gain on revaluation of InterCure securities; the comparable 2019 amount was a US$574,000 loss. The investment was carried at US$2.411 million at year-end, versus US$2.273 million in 2019. Results therefore include material non-operating fair-value movements. No meaningful revenue or gross-margin comparison is available.
At December 31, 2020, cash and cash equivalents were US$3.631 million (versus US$4.455 million), working capital was US$5.867 million (versus US$6.598 million), total assets were US$6.503 million, and shareholders’ equity was US$6.249 million. Accounts payable were US$254,000; the filing reports no long-term liabilities and says the company does not use credit facilities. The filing gives no separate conventional debt balance. Investing activities provided US$32,000, and financing activities provided no cash in 2020.
Material changes, outlook and risks
- Management reported that existing cash should fund activities for at least 12 months from the report date, but expects further losses and negative operating cash flow. Additional capital is needed for clinical development; failure to raise it on acceptable terms could require reduced development, asset sales or sublicensing.
- Clinical-trial spending is being curtailed pending adequate funding or a strategic partner. Subject to financing or collaboration, the company plans an international SLE study, a Phase II SS study and further pipeline expansion; the filing provides no firm start dates or budgets.
- Teva’s prior Phase II PRELUDE study of hCDR1 did not meet its primary SLEDAI endpoint. The company cites encouraging secondary BILAG findings, particularly for a 0.5 mg weekly dose. The FDA indicated BILAG could be an acceptable primary endpoint for a future study, subject to financing.
- COVID-19 had no material effect on operations or financial results as of the report’s issuance, but broader economic and market effects remained uncertain.
- Key risks include clinical and regulatory failure, limited funding and potential shareholder dilution, reliance on third-party manufacturers and licensors, low ADS trading volume, and foreign-exchange exposure. The hCDR1 patent families include expirations in 2022 and 2024; the company also disclosed an unpaid US$127,000 Yeda-related liability. Management reported no impairment of the hCDR1 intangible asset.
- The company reported four part-time service providers and no employees as of March 15, 2021. It has never paid cash dividends and does not anticipate doing so in the foreseeable future. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end; the auditor did not provide an ICFR opinion.
Most important facts for investors to verify
- Cash runway and financing needs against the stated minimum 12-month runway, particularly the funding required to restart planned trials.
- Clinical strategy and evidence for hCDR1, including PRELUDE’s failed primary endpoint, the proposed BILAG endpoint and any partnership or trial progress.
- Capitalization and potential dilution: the filing reports 514,205,799 ordinary shares outstanding at year-end and 245,000,000 ordinary shares underlying outstanding warrants.
- Share-count disclosures are inconsistent: a later major-shareholder table uses 789,205,799 ordinary shares, rather than the 514,205,799 reported elsewhere. Confirm the correct denominator and ownership percentages.
- InterCure investment valuation and liquidity, Yeda license obligations and patent-expiry implications, and compliance with Nasdaq continued-listing requirements.